Skip to content

Medicines and devices

Naltrexone-bupropion (Contrave)

Contrave is an extended-release tablet combining naltrexone and bupropion, approved by the FDA in 2014 for chronic weight management in adults with obesity or overweight.

DefinitionContrave is an extended-release tablet combining naltrexone and bupropion, approved by the FDA in 2014 for chronic weight management in adults with obesity or overweight.

What it means

Contrave combines bupropion, an antidepressant also used to help people quit smoking, with naltrexone, which blocks opioid receptors. Together they act on brain areas that control appetite and cravings. The FDA approved it in 2014, and the dose is stepped up over about four weeks.

Because bupropion is an antidepressant, the label carries a boxed warning about suicidal thoughts and behavior, especially in young people. It can also raise blood pressure and heart rate and, rarely, cause seizures.

It should not be used with uncontrolled high blood pressure, a seizure disorder, an eating disorder such as bulimia or anorexia, or with opioid medicines, since naltrexone blocks them. Nausea, constipation, headache, dizziness and trouble sleeping are common.

The label advises stopping if weight loss is less than 5% after 12 weeks on the full dose.

Why it matters

Contrave is a pill option that targets cravings, but its opioid and mental health warnings rule it out for some people.

Related tools

Related terms

Sources

  1. DailyMed: Contrave label

Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error